Loading stock data…
TGTX
$43.14+0.28 (+0.65%)
After Hours$43.15+0.01 (+0.02%)· Last close May 11
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
TG Therapeutics, Inc. in the Healthcare sector is trading at $43.14. The stock is currently near its 52-week high of $44.65, remaining 35.0% above its 200-day moving average. Technical signals show overbought RSI of 71 and bullish MACD crossover, explaining why TGTX maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 71) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$43.14
Potential Upside
46.2%
Whystock Fair Value$63.09
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus7 analysts
Buy
Mean target$48.14+11.6%
Range$17.00 – $70.00
Fundamentals
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMV...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.01B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
13.58
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.75
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
9.33%
Volume
Today's trading volume
2.78M
Recent News
Signal Says Which Biotech to Buy This Week
TG Therapeutics stocks is flashing a "buy" signal right now
Why TG Therapeutics (TGTX) Is Up 27.4% After Raising 2026 Revenue Guidance On BRIUMVI Strength
TG Therapeutics recently reported its first-quarter 2026 results, with revenue rising to US$204.92 million and net income reaching US$19.78 million, and raised its full-year 2026 total global revenue target to about US$925 million, including US$885 million to US$900 million from BRIUMVI U.S. net product revenue. The company’s decision to lift revenue guidance on the back of strong BRIUMVI uptake and record patient starts underlines how one product is increasingly shaping TG Therapeutics’...
Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position
This clinical-stage biotech develops oral therapeutics for chronic diseases, targeting large global markets with unmet medical needs.
Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition technology.
Assessing TG Therapeutics (TGTX) Valuation After Recent Share Price Momentum
Why TG Therapeutics (TGTX) is back on many investors’ radar TG Therapeutics (TGTX) has drawn fresh attention after recent share price moves, with returns of 27% over the past week and about 49% over the past 3 months signaling renewed market focus. For investors tracking the pharmaceutical and biotech space, those short term gains sit alongside a 47% year to date return and a 27% 1 year total return, inviting closer scrutiny of what is driving current expectations. See our latest analysis for...